Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
- 22 April 2019
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 42 (6), 1075-1080
- https://doi.org/10.2337/dc18-2028
Abstract
OBJECTIVE Increases in serum calcitonin, a tumor marker for medullary thyroid carcinoma (MTC), have been associated with glucagon-like peptide 1 receptor agonist use in some preclinical studies. We report calcitonin changes in exenatide-treated and placebo-administered participants and MTC incidence in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) and consider the impact of within-trial calcitonin monitoring. RESEARCH DESIGN AND METHODS EXSCEL participants were randomized 1:1 to once-weekly exenatide 2 mg or placebo. Serum calcitonin was measured at baseline (with trial medication discontinued if >40 ng/L) and annually thereafter (with trial medication discontinued if ≥50 ng/L). Median calcitonin concentrations were calculated at each time point, and thyroid malignancies were collected prospectively. Data regarding follow-up after an elevated calcitonin were collected retrospectively. RESULTS At baseline, 52 (30 exenatide and 22 placebo) participants had calcitonin >40 ng/L, and during follow-up an additional 23 participants (15 exenatide and 8 placebo) had calcitonin ≥50 ng/L in the intention-to-treat population. Median calcitonin concentrations were similar between treatment groups at baseline with no increase over time. Confirmed MTC occurred in three participants (2 exenatide and 1 placebo), all of whom had significantly elevated baseline calcitonin values (413, 422, and 655 ng/L). CONCLUSIONS During a median 3.2 years’ follow-up, no change in serum calcitonin was seen with exenatide therapy. The three confirmed cases of MTC all occurred in participants with markedly elevated baseline calcitonin levels, measured prior to trial medication administration. Regular calcitonin monitoring identified no additional cases of MTC, suggesting no benefit of routine calcitonin monitoring during exenatide treatment.Keywords
Funding Information
- Amylin Pharmaceuticals, Inc.
This publication has 14 references indexed in Scilit:
- No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER TrialDiabetes Care, 2017
- A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy.Thyroid Research, 2017
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2016
- Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trialAmerican Heart Journal, 2015
- Screening for Medullary Thyroid Carcinoma with Serum Calcitonin Measurements in Patients with Thyroid Nodules in the United States and CanadaThyroid®, 2011
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell ProliferationEndocrinology, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Correlation between gender and spontaneous C-cell tumors in the thyroid gland of the Wistar ratCell and tissue research, 1999
- The Effects of Xenobiotics on the Structure and Function of Thyroid Follicular and C-CellsToxicologic Pathology, 1989